Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 30 · below the Ichimoku cloud · RSI 40 · MACD below its signal
None of the 29 investors followed here reported a position in PNV.AX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PNV.AX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Hoare (Leon)Non Executive Chairman | — | 15.8K | — |
| Jun 29, 2026 | Peatey (Bruce)Chief Executive Officer | — | 55.6K | — |
| Mar 11, 2026 | Douglas (Robert)Director (Non-Executive) | Purchase at price 0.47 per share. | 151K | $71.00K |
| Feb 24, 2026 | Hoare (Leon)Director (Non-Executive) | Purchase at price 0.67 per share. | 30K | $20.00K |
| Feb 23, 2026 | Lumsden (Andrew Stuart)Director (Non-Executive) | Purchase at price 0.64 per share. | 100K | $64.45K |
| Sep 18, 2025 | Williams (David John)Non Executive Chairman | Purchase at price 1.05 per share. | 55K | $58.00K |
| Sep 16, 2025 | Elliot (Robyn)Director (Non-Executive) | Purchase at price 1.06 per share. | 20K | $21.28K |
| Sep 14, 2025 | Williams (David John)Non Executive Chairman | Purchase at price 1.00 per share. | 50K | $50.02K |
| Sep 11, 2025 | Williams (David John)Non Executive Chairman | Purchase at price 0.93 per share. | 61.3K | $57.15K |
| Sep 10, 2025 | Hoare (Leon)Director (Non-Executive) | Purchase at price 0.93 per share. | 20K | $18.53K |
| Sep 10, 2025 | Williams (David John)Non Executive Chairman | Purchase at price 0.92 per share. | 31K | $28.48K |
| Sep 9, 2025 | Williams (David John)Non Executive Chairman | Purchase at price 0.93 per share. | 37K | $34.37K |
| Jun 29, 2025 | Gielen (Jan)Chief Financial Officer | — | 345K | — |
| Jan 9, 2025 | Williams (David John)Non Executive Chairman | Sale at price 1.25 per share. | 750 | $935 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.5 | -4.9 | -3.1 | 7.0 | 22.0 | -24.6 | -6.0 | 16.2 | -8.0 | -3.2 | −27.2% | ||
| 2025 | 2.5 | -31.6 | -19.9 | 5.7 | 8.3 | -8.8 | 7.9 | 1.9 | 8.4 | -7.4 | -6.8 | 0.0 | −39.7% |
| 2024 | 15.1 | 19.7 | -3.9 | -6.4 | 9.8 | 8.9 | 9.4 | -12.7 | 11.5 | -21.1 | 6.8 | -7.3 | +23.3% |
| 2023 | 24.3 | -2.0 | -27.2 | -8.9 | -8.9 | 4.0 | 4.9 | -8.0 | -12.4 | -11.5 | 19.0 | 20.4 | −18.1% |
| 2022 | -14.1 | -23.7 | 9.5 | -13.2 | 30.0 | 9.7 | 21.0 | -20.1 | -0.8 | 53.8 | 1.0 | 0.0 | +32.5% |
| 2021 | -32.2 | -8.4 | 12.4 | 10.7 | -9.7 | 4.1 | -20.2 | -0.9 | -13.7 | -5.5 | -19.8 | 4.5 | −60.7% |
| 2020 | 42.1 | -18.2 | -29.9 | 35.2 | 26.7 | -7.6 | -13.8 | 0.9 | 0.0 | 17.6 | 23.5 | 20.9 | +97.0% |
| 2019 | 14.3 | 16.2 | -5.1 | 38.0 | 15.9 | 28.3 | 3.9 | 26.9 | 5.4 | 5.6 | -20.8 | 10.1 | +231.1% |
| 2018 | -7.7 | 5.2 | 5.0 | -1.9 | 17.3 | -12.3 | -4.7 | 10.8 | 6.2 | -1.7 | 1.7 | -0.8 | +14.4% |
| 2017 | -5.2 | 5.5 | -6.9 | -11.1 | -8.3 | -4.5 | -4.8 | 7.5 | 30.2 | 17.9 | 15.2 | 36.8 | +79.3% |
| 2016 | -12.1 | 13.7 | -3.4 | 3.6 | -5.2 | 1.8 | 0.0 | -3.6 | 7.4 | 6.9 | -11.3 | 5.5 | −0.0% |
| 2015 | -6.6 | -1.2 | -14.3 | 11.1 | -2.5 | 15.4 | 16.7 | -4.8 | 35.0 | 0.0 | 18.5 | 81.2 | +218.7% |
| 2014 | -5.1 | 24.0 | 39.8 | -15.4 | -9.1 | 5.0 | 14.3 | -16.7 | -5.0 | -3.2 | 1.1 | -2.2 | +15.2% |
| 2013 | 2.3 | 0.0 | 11.1 | 70.0 | -5.9 | -12.5 | 4.3 | 12.3 | -1.2 | -8.6 | 8.1 | -1.2 | +79.5% |
| 2012 | -8.9 | -11.8 | 28.9 | -1.7 | -22.8 | 36.4 | -18.3 | 0.0 | -6.1 | 10.9 | -11.8 | -2.2 | −21.4% |
| 2011 | 7.7 | 46.4 | 17.1 | 33.3 | 31.2 | -22.6 | -16.9 | 7.4 | 3.4 | 0.0 | 0.0 | -6.7 | +115.4% |
| 2010 | 3.3 | 6.5 | 0.0 | -9.1 | -6.7 | -10.7 | 0.0 | -4.0 | 0.0 | 8.3 | 3.8 | -3.7 | −13.3% |
| 2009 | -3.8 | -16.0 | 9.5 | 17.4 | 25.9 | -20.6 | 11.1 | 6.7 | 0.0 | -6.3 | 0.0 | 0.0 | +15.4% |
| 2008 | -22.0 | 9.4 | -14.3 | 26.7 | 7.9 | 2.4 | -9.5 | 0.0 | -15.8 | -3.1 | -12.9 | -3.7 | −36.6% |
| 2007 | 13.9 | -82.4 | -12.1 | -10.3 | 7.7 | -7.1 | 0.0 | -55.4 | 1.7 | -5.1 | -16.1 | -12.8 | −95.0% |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Buy / hold / sell counts
No recent headlines.